1-Amino-4-methylhexan-3-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Amino-4-methylhexan-3-one
• 英文别名: 1-amino-4-methylhexan-3-one
• 化学式: C₇H₁₅NO
• 分子量: 129.2
• InChiKey: CLKGZJJIRWPHOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• ORAL CARE METHODS AND COMPOSITIONS UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS
  申请人：Synedgen Inc.

  公开号：US20180049965A1

  公开（公告）日：2018-02-22

  Described herein is a method of reducing bacteria in the mouth of a subject, the method comprising contacting (e.g., rinsing) the mouth with an effective amount of a composition comprising a soluble derivatized chitosan, thereby reducing bacteria in the mouth of the subject.
• [EN] DNP AND DNP PRODRUG TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL, CONCUSSION, DRY EYE DISEASE, AND/OR METABOLIC DISEASES<br/>[FR] TRAITEMENT PAR LE DNP ET DES PROMÉDICAMENTS DU DNP DES MALADIES NEUROMUSCULAIRES, NEURODÉGÉNÉRATIVES, AUTO-IMMUNES, DES MALADIES DU DÉVELOPPEMENT, DE LA COMMOTION, DU SYNDROME DE L'ŒIL SEC, ET/OU DES MALADIES MÉTABOLIQUES
  申请人：MITOCHON PHARMACEUTICALS LLC

  公开号：WO2017155940A1

  公开（公告）日：2017-09-14

  A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMAI, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4- dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof.
• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
  申请人：FOGHORN THERAPEUTICS INC

  公开号：WO2020160192A1

  公开（公告）日：2020-08-06

  The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.